Antitumorigenic Effects of Cannabinoids beyond Apoptosis

  title={Antitumorigenic Effects of Cannabinoids beyond Apoptosis},
  author={Nadine Freimuth and Robert M. Ramer and Burkhard Hinz},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={336 - 344}
According to the World Health Organization, the cases of death caused by cancer will have been doubled until the year 2030. By 2010, cancer is expected to be the number one cause of death. Therefore, it is necessary to explore novel approaches for the treatment of cancer. Over past years, the antitumorigenic effects of cannabinoids have emerged as an exciting field in cancer research. Apart from their proapoptotic and antiproliferative action, recent research has shown that cannabinoids may… 

Figures and Tables from this paper

Cannabinoid-associated cell death mechanisms in tumor models (review).
The results reported here suggest that the exploration of molecular mechanisms induced by cannabinoids in cancer cells can contribute to the development of safe and effective treatments in cancer therapy.
Cancer therapy-The role of cannabinoids and endocannabinoids
Recent advances regarding ongoing research of cannabinoids and endocannabinoids in various cancer types are presented.
The role of cannabinoids in the treatment of cancer.
The antitumor effects of cannabinoids (whether in monotherapy or in combination with other cancer therapies) have promising potential in the treatment of cancer patients.
The antitumor action of cannabinoids on glioma tumorigenesis.
This work presents the available experimental and clinical data, to date, regarding the antitumor action of cannabinoids on the tumorigenesis of gliomas.
Antitumorigenic targets of cannabinoids – current status and implications
  • R. Ramer, B. Hinz
  • Biology, Chemistry
    Expert opinion on therapeutic targets
  • 2016
Drugs aiming at the endocannabinoid system may represent potential 'antimetastatics' for an upgrade of a future armamentarium against cancer diseases because of the comparatively good safety profile of cannabinoid compounds.
The Synthetic Cannabinoid WIN 55,212-2 Elicits Death in Human Cancer Cell Lines.
The application of WIN 55,212-2 was found to trigger cell death in the investigated cell lines, and the decline in lung cancer and testicular cancer cell viability seems to have been caused by apoptosis.
The pharmacological basis for application of cannabidiol in cancer chemotherapy
The pharmacological basis for therapeutic application of CBD is constructed on the scientific data for its antitumor activity, extensively provided studies in vitro and in vivo in animal tumor models, and available data on the safety profile of clinically approved CBD products.
Assessment of Cannabinoids Agonist and Antagonist in Invasion Potential of K562 Cancer Cells
The findings clarifies that CB1 receptors are responsible for anti-invasive effects in the K562 cell line and shows that WIN 55212-2 considerably reduced cancer cell invasiveness, while AM251 exhibited a converse effect.
Cannabidiol as potential anticancer drug
The present review will focus on the efficacy of CBD in the modulation of different steps of tumourigenesis in several types of cancer and highlights the importance of exploring CBD/CBD analogues as alternative therapeutic agents.
New insights into antimetastatic and antiangiogenic effects of cannabinoids.
  • R. Ramer, B. Hinz
  • Biology
    International review of cell and molecular biology
  • 2015


Inhibition of tumor angiogenesis by cannabinoids
It is shown that local administration of a nonpsychoactive cannabinoid to mice inhibits angiogenesis of malignant gliomas as determined by immunohistochemical analyses and vascular permeability assays.
Cannabinoids and cell fate.
Loss of cannabinoid receptor 1 accelerates intestinal tumor growth.
The genetic and pharmacologic studies reveal that loss or inhibition of CB1 accelerated intestinal adenoma growth in Apc(Min/+) mice whereas activation ofCB1 attenuated intestinal tumor growth by inducing cell death via down-regulation of the antiapoptotic factor survivin.
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor
The cannabinoid quinone HU-331 is a highly specific inhibitor of topoisomerase II, compared with most known anticancer quinones, and might represent a new potent anticancer drug.
Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation
It is shown that intratumoral administration of Δ9-tetrahydrocannabinol and the synthetic cannabinoid agonist WIN-55,212-2 induced a considerable regression of malignant gliomas in Wistar rats and in mice deficient in recombination activating gene 2.
Cannabinoid receptors as novel targets for the treatment of melanoma
Evaluated the efficacy of cannabinoid receptor agonists, a new family of potential antitumoral compounds, at skin melanoma, and found that Cannabinoid antiproliferative action on melanoma cells was due, at least in part, to cell cycle arrest at the G1‐S transition.
Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors.
It is shown that the CB(1) and theCB(2) receptor are expressed in normal skin and skin tumors of mice and humans and support a new therapeutic approach for the treatment of skin tumors.
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
The current data demonstrate that CB2 cannabinoid receptors expressed on malignancies of the immune system may serve as potential targets for the induction of apoptosis, and because CB2 agonists lack psychotropic effects, they may Serve as novel anticancer agents to selectively target and kill tumors of immune origin.
Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.
It is shown that local administration of the selective CB(2) agonist JWH-133 at 50 microg/day to Rag-2(-/-) mice induced a considerable regression of malignant tumors generated by inoculation of C6 glioma cells, and showed that selective activation of the CB( 2) receptor signaled apoptosis via enhanced ceramide synthesis de novo.
The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation.
The data suggest that anandamide blocks human breast cancer cell proliferation through CB1-like receptor-mediated inhibition of endogenous Prolactin action at the level of prolactin receptor.